Abstract
To the Editor: An infrequently reported cutaneous complication of biologic treatment is the onset of localized scleroderma or morphea. Given the increasing use of biologic therapy worldwide, it is essential for health care providers to anticipate and manage potential adverse effects. This review aims to summarize reports of morphea development in patients receiving biologic therapies targeting inflammatory pathways implicated in psoriasis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
